Cover Image
Read Now

Darunavir/Cobicistat (Prezcobix)

The objective of this systematic review is to examine the beneficial and harmful effects of cobicistat-boosted darunavir (DRV/COBI) 800 mg/150 mg for the treatment of HIV-1 infection in antiretroviral treatment-naive and treatment-experienced patients without darunavir (DRV) resistance-associated mu...

Full description

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2015 Jul, 2015
Series:Common drug review
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 01175nam a2200217 u 4500
001 EB002002193
003 EBX01000000000000001165094
005 00000000000000.0
007 tu|||||||||||||||||||||
008 210907 r ||| eng
245 0 0 |a Darunavir/Cobicistat (Prezcobix)  |h Elektronische Ressource  |c prepared by the Canadian Agency for Drugs and Technologies in Health 
260 |a Ottawa (ON)  |b Canadian Agency for Drugs and Technologies in Health  |c 2015 Jul, 2015 
300 |a 1 online resource  |b illustrations 
505 0 |a Includes bibliographical references 
710 2 |a Canadian Agency for Drugs and Technologies in Health 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a Common drug review 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK362499  |3 Volltext 
082 0 |a 615 
520 |a The objective of this systematic review is to examine the beneficial and harmful effects of cobicistat-boosted darunavir (DRV/COBI) 800 mg/150 mg for the treatment of HIV-1 infection in antiretroviral treatment-naive and treatment-experienced patients without darunavir (DRV) resistance-associated mutations (RAMs) 

Similar Items